title: Multi-centre phase II study of low dose intravesical epirubicin in the treatment of superficial bladder cancer. Yorkshire and Scottish Urological Cancer Research Groups.
abstract: Forty patients with multiple recurrent superficial bladder tumours received an 8-week course of weekly instillations of 4' epirubicin 30 mg in 50 ml saline. The overall response rate was 58% and side effects were minimal.
authors.affiliation: Department of Urology, St James's University Hospital, Leeds.
authors.forename: P
authors.initials: P
authors.lastname: Whelan
authors.forename: J A
authors.initials: JA
authors.lastname: Cumming
authors.forename: W H
authors.initials: WH
authors.lastname: Garvie
authors.forename: T B
authors.initials: TB
authors.lastname: Hargreave
authors.forename: D
authors.initials: D
authors.lastname: Kirk
authors.forename: D W
authors.initials: DW
authors.lastname: Newling
authors.forename: M R
authors.initials: MR
authors.lastname: Robinson
authors.forename: P H
authors.initials: PH
authors.lastname: Smith
mesh_terms: D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000473:pathology; D015251:Epirubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D015251:Epirubicin